Roger M. Perlmutter, M.D., Ph.D., joined Merck in 2013 as the executive vice president and president of Merck Research Laboratories. He was formerly executive vice president and head of R&D at Amgen from January 2001 to February 2012. During his tenure, he oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis.
Prior to joining Amgen, Dr. Perlmutter held roles of increasing responsibility at Merck Research Laboratories, culminating in his appointment to executive vice president of Worldwide Basic Research and Preclinical Development. He joined Merck as a senior vice president in February 1997. Most recently, he served as a director of several biotechnology companies and was a science partner at The Column Group, a biotechnology-focused venture capital firm.
Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington and also served as chairman of its Department of Immunology where he was a Howard Hughes Medical Institute investigator. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to this, he was a lecturer in the Division of Biology at the California Institute of Technology.
Dr. Perlmutter graduated from Reed College in Portland, Ore., and received his M.D. and Ph.D. degrees from Washington University in St. Louis, Mo. He completed his clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco.Dr. Perlmutter is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.
Copyright. © 2009-2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.